Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with cutaneous melanoma. Immunotherapy (IT) is generally well tolerated, but an increasing area of investigation concerns the optimal treatment duration of anti-programmed cell death-1 (anti-PD1) regimens to limit the immune...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Giacomo Triggiano, Gaetano Pezzicoli, Marco Tucci
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2025-04-01
Serie:	Biomolecules
Soggetti:	cutaneous melanoma immune checkpoint inhibitors immune-related adverse events anti-PD1 combo-immunotherapy treatment discontinuation
Accesso online:	https://www.mdpi.com/2218-273X/15/5/651
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!